人类孕烷受体遗传变异对遗传药理学和药物代谢的影响

中国临床药理学与治疗学 ›› 2007, Vol. 12 ›› Issue (8): 845-849.

人类孕烷受体遗传变异对遗传药理学和药物代谢的影响

刘艳^1,3, 尹又², 陈尧³, 周宏灏³

¹上海交通大学附属新华医院药剂科, 上海 200092;
²上海长征医院神经内科, 上海 200003;
³中南大学临床药理研究所, 长沙 410078, 湖南

收稿日期:2007-04-06 修回日期:2007-06-15 出版日期:2007-08-26 发布日期:2020-10-27
通讯作者: 周宏灏, 男, 博士生导师, 院士, 研究方向:临床药理学、遗传药理学。Tel:0731-4805379 E-mail:hhzhou@public.hn.cs
作者简介:刘艳,女,硕士,研究方向:临床药理学、遗传药理学。Tel:13795426099 E-mail:liuyan160@163.com
基金资助:
国家自然科学基金资助项目(30572226)

Effects of genetics variants of pregnant xenobiotic receptor and on pharmacogenetics and drug metabolism

LIU Yan^1,3, YIN You², CHEN Yao³, ZHOU Hong-hao³

¹Department of Pharmacy, Xinhua Hospital, Shanghai Jiaotong University, Shanghai 200092, China;
²Department of Newrology, Changzhen Hospital, the Second Military Medical University, Shanghai 20003, China;
³Institute of Clinical Pharmacology, Central South University, Changsha 410078, Hunan, China

Received:2007-04-06 Revised:2007-06-15 Online:2007-08-26 Published:2020-10-27

摘要/Abstract

摘要： CYP3A4 和多药耐药相关基因(MDR1)等在药物清除和处置中起重要调节作用, 孕烷受体(PXR)通过调节上述基因间接影响药物诱导反应。因此,PXR 的基因变异会对临床药物-药物相互作用产生极其重要的影响。本文将对目前已经发现的PXR基因变异及突变导致的功能影响作一综述。同时,因为可变剪接在个体差异和组织特异性表达中起着不可或缺的作用, 本文将一并讲述。全面考虑PXR的基因突变和mRNAs 可变剪接最终将有助于评价药物联合运用合理性和推测药物治疗效应。

关键词: 孕烷受体, 变异, 单核苷酸多态性, 可变剪接, 药物代谢, 遗传药理学

Abstract: The orphan nuclear receptor PXR influence drug-induced effects indirectly by mediating transcription of genes CYP3A4 and MDR1 which play important roles in drug clearance and disposition.Thus, genetic variability in PXR will contribute significantly to drugdrug interactions in clinical practice.This review describes common PXR genetic variants that have been identified to date in the human population and the functional consequence of these variant alleles.In addition, this article also described alternatively spliced variants of PXR which may also contribute to individual variability as well as tissue specific expression.Identification of PXR genetic variants and alternatively spliced mRNAs may ultimately conduce to the evaluation of rationality when drugs given in combination and the predictions of therapeutic effects.

Key words: pregnant xenobiotic receptor, genetics variants, single nucleotide polymorphism, splicing variant, drug metabolism, pharmacogenetics

中图分类号:

R968
R969.1

刘艳, 尹又, 陈尧, 周宏灏. 人类孕烷受体遗传变异对遗传药理学和药物代谢的影响[J]. 中国临床药理学与治疗学, 2007, 12(8): 845-849.

LIU Yan, YIN You, CHEN Yao, ZHOU Hong-hao. Effects of genetics variants of pregnant xenobiotic receptor and on pharmacogenetics and drug metabolism[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(8): 845-849.

参考文献

1 Nishimura M, Naito S, Yokoi T.Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies[J].Drug Metab Pharmacokinet, 2004;19:135-149.
2 Medina-Diaz IM, Arteaga-Illan G, de Leon MB, et al.Pregnane X receptor-dependent induction of the CYP3A4 gene by o, p'-1, 1, 1,-trichloro-2, 2-bis (p-chlorophenyl)ethane[J].Drug Metab Dispos, 2007;35:95-102.
3 Stanley LA, Horsburgh BC, Ross J, et al.PXR and CAR:nuclear receptors which play a pivotal role in drug disposition and chemical toxicity[J].Drug Metab Rev, 2006;38:515-597.
4 Itoh M, Nakajima M, Higashi E, et al.Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha [J].J Pharmacol Exp Ther, 2006;319:693-702.
5 Al-Dosari MS, Knapp JE, Liu D.Activation of human CYP2C9 promoter and regulation by CAR and PXR in mouse liver[J]. Mol Pharm, 2006;3:322-328.
6 Lemaire G, Mnif W, Pascussi JM, et al.Identification of new human pregnane X receptor ligands among pesticides using a stable reporter cell system[J].Toxicol Sci, 2006;91:501-509.
7 Huwyler J, Wright MB, Gutmann H, et al.Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin[J].Curr Drug Metab, 2006;7:119-126.
8 Eloranta JJ, Meier PJ, Kullak-Ublick GA.Coordinate transcriptional regulation of transport and metabolism[J].Methods Enzymol, 2005;400:511-530.
9 Kurose K, Ikeda S, Koyano S, et al.Identification of regulatory sites in the human PXR (NR1I2)promoter region[J].Mol Cell Biochem, 2006;281:35-43.
10 Gerbal-Chaloin S, Pichard-Garcia L, Fabre JM, et al.Role of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide[J].Cell Signal, 2006;18:740-750.
11 Ruhl R, Sczech R, Landes N, et al.Carotenoids and their metabolites are naturally occurring activators of gene expression via the pregnane X receptor[J].Eur J Nutr, 2004;43:336-343.
12 Maher JM, Cheng X, Slitt AL, et al.Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver [J].Drug Metab Dispos, 2005;33:956-962.
13 Cheng X, Maher J, Dieter MZ, et al.Regulation of mouse organic anion-transporting polypeptides (Oatps)in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways[J].Drug Metab Dispos, 2005;33: 1276-1282.
14 Chang TK, Bandiera SM, Chen J.Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels[J].Drug Metab Dispos, 2003;31:7-10.
15 Zhang J, Kuehl P, Green ED, et al.The human pregnane X receptor:genomic structure and identification and functional characterization of natural allelic variants[J].Pharmacogenetics, 2001;11:555-572.
16 Koyano S, Kurose K, Ozawa S, et al.Eleven novel single nucleotide polymorphisms in the NR1I2 (PXR) gene, four of which induce non-synonymous amino acid alterations[J].Drug Metab Pharmacokinet, 2002;17:561-565.
17 LimYP, Liu CH, Shyu LJ, et al.Functional characterization of a novel polymorphism of pregnane X receptor, Q158K, in Chinese subjects[J].Pharmacogenet Genomics, 2005;15:337-341.
18 Uno Y, Sakamoto Y, Yoshida K, et al.Characterization of six base pair deletion in the putative HNF1-binding site of human PXR promoter[J].J Hum Genet, 2003;48:594-597.
19 Bertilsson G, Heidrich J, Svensson K, et al.Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction[J].Proc Natl Acad Sci USA, 1998;95: 12208-12213.
20 Lamba V, Yasuda K, Lamba JK, et al.PXR(NR1I2):splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators[J].Toxicol Appl Pharmacol, 2004;199:251-265.
21 Vyhlidal CA, Rogan PK, Leeder JS.Development and refinement of pregnane X receptor (PXR)DNA binding site model using information theory:insights into PXR-mediated gene regulation[J].J Biol Chem, 2004;279:46779-46786.
22 Lamba J, Lamba V, Schuetza E.Genetic Variants of PXR (NR1I2) and CAR (NR1I3) and Their Implications in Drug Metabolism and Pharmacogenetics[J].Curr Drug Metab, 2005; 6:369-383.
23 Mensah-Osman EJ, Thomas DG, Tabb MM, et al.Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines[J].Cancer, 2007; 109:957-965.
24 Hustert E, Zibat A, Presecan, et al.Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4[J].Drug Metab Dispos, 2001;29:1454-1459.

[1]	李坤, 李璐璐, 李楠楠, 胡卫红, 周建超. 成人肾移植术后血糖控制和CYP3A5基因多态性对他克莫司谷浓度的影响[J]. 中国临床药理学与治疗学, 2023, 28(7): 767-774.
[2]	史革鑫, 崇锐, 贺坤, 吴海棠, 周宇, 顿中军, 温清, 张继国, 张荣. 吗替麦考酚酯胶囊在中国健康男性受试者空腹及餐后状态下的完全重复交叉设计的生物等效性研究[J]. 中国临床药理学与治疗学, 2022, 27(11): 1255-1263.
[3]	周晗, 刘晓东. 生理药代动力学模型在创新药物评价中应用及其若干问题的思考[J]. 中国临床药理学与治疗学, 2021, 26(8): 889-913.
[4]	张远金, 黄盛博, 刘洁, 王昕. 药物代谢创新模型：基因编辑大鼠和小肠3D类器官[J]. 中国临床药理学与治疗学, 2021, 26(8): 914-922.
[5]	徐国防, 高盼, 刘平, 张孝磊, 荆萃, 张翠翠, 荆会霞, 李晓苏, 齐琦. 卡培他滨片在肿瘤患者中的生物等效性研究[J]. 中国临床药理学与治疗学, 2020, 25(10): 1119-1124.
[6]	尹子毅，王峰，赵梦，张铁，王丕琳. 卡培他滨为基础一线方案治疗Her2阴性转移性乳腺癌的单中心回顾性研究及TYMP基因多态性分析[J]. 中国临床药理学与治疗学, 2019, 24(9): 1002-1008.
[7]	陈泓竹，刘建明，周芳，贾元威，王广基，张经纬. 内源性物质代谢对药物代谢处置的影响及机制研究[J]. 中国临床药理学与治疗学, 2019, 24(5): 580-588.
[8]	王傲，蔡晶晶，柏建岭，刘月，于宣宣，陈峰，赵杨，于浩. 高变异药物平均生物等效性试验中两种重复交叉设计的样本量估计[J]. 中国临床药理学与治疗学, 2019, 24(2): 164-170.
[9]	谢商宸，李玮，廖萍，贺毅憬，Howard L. Mcleod. 全身麻醉药物遗传药理学研究进展[J]. 中国临床药理学与治疗学, 2018, 23(2): 217-222.
[10]	王小青，周杰兆，程泽能，姜德建. 失重环境药物代谢动力学研究[J]. 中国临床药理学与治疗学, 2017, 22(6): 709-712.
[11]	陈涛，严永兴，沈咏慧. 血清B型利钠肽前体和血压变异性在非心源性急性脑梗死患者临床应用中的价值[J]. 中国临床药理学与治疗学, 2017, 22(5): 570-573.
[12]	王瑜，仲云熙，金孝亮，谷世寅，彭英，尹莉芳，贾元威，孙建国，王广基. 高效液相色谱-串联质谱法测定犬血浆中的普瑞巴林及在药代动力学中的应用[J]. 中国临床药理学与治疗学, 2016, 21(7): 731-738.
[13]	何春远，孙华，谢海棠. 高变异药物生物等效性试验及量化评价[J]. 中国临床药理学与治疗学, 2016, 21(7): 721-730.
[14]	刘英姿，曾飞跃，肖乐东，王果. 焦磷酸测序分析CTR1基因多态性方法的建立[J]. 中国临床药理学与治疗学, 2016, 21(6): 673-677.
[15]	沈淑娇，张志荣，张林林，樊玉娟，谭波，李玥，蒋健，裘福荣. 甘草水煎液对α-萘异硫氰酸酯诱导的肝内胆汁淤积性损伤的防治及其机理研究[J]. 中国临床药理学与治疗学, 2016, 21(12): 1321-1327.